|
EPCORE FL-2: Phase 3 trial of epcoritamab with rituximab and lenalidomide (R2) vs chemoimmunotherapy or R2 in previously untreated follicular lymphoma. |
|
|
|
Consulting or Advisory Role - Abbvie; BeiGene; Bristol-Myers Squibb/Celgene; Kite/Gilead; Roche |
Speakers' Bureau - Genmab; Hartley Taylor Medical |
Research Funding - Genmab (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - BeiGene; Hartley Taylor Medical; Roche |
|
|
Honoraria - Abbvie; Adaptive Biotechnologies; AstraZeneca; Janssen; Merck |
Consulting or Advisory Role - Abbvie; Ascentage Pharma; AstraZeneca; BeiGene; Genentech; Genmab; Janssen; Loxo/Lilly |
Research Funding - Abbvie (Inst); Adaptive Biotechnologies (Inst); Genentech (Inst); Pharmacyclics (Inst); Sana Biotechnology (Inst) |
Travel, Accommodations, Expenses - Merck |
|
|
No Relationships to Disclose |
|
|
Leadership - Abbvie; Bristol-Myers Squibb/Celgene; Genentech (Inst); Genmab; Gilead Sciences (Inst) |
Research Funding - Celgene (Inst); Genentech (Inst); Gilead Sciences (Inst); Verastem (Inst) |
Travel, Accommodations, Expenses - Gilead Sciences; Roche |
|
|
|
Stock and Other Ownership Interests - Abbvie |
|
|
|
Stock and Other Ownership Interests - Abbvie |
|
|
|
Stock and Other Ownership Interests - Abbvie |
|
|
|
Stock and Other Ownership Interests - Abbvie |
|
|
|
Stock and Other Ownership Interests - Genmab |
|
|
Honoraria - Amgen; Gilead Sciences; Incyte; Janssen-Cilag; Novartis; Roche; Takeda |
Consulting or Advisory Role - Gilead Sciences; Incyte; Novartis; Novartis; Roche; Takeda |
Research Funding - Amgen Foundation (Inst); Bristol Myers Squibb Foundation (Inst) |
Travel, Accommodations, Expenses - Gilead Sciences; Incyte; Janssen-Cilag; Roche |